Replies to post #78756 on Biotech Values

[DewDiligence]

EXEL – The deadpan reply in your first post was funny, but this is a deadly serious topic for biotech investors.

…it shows how the criteria in tumor response in press releases cannot be relied upon until the independent reviews are performed and announced.

Quite so; moreover, many phase-2 trials do not even have independent reviews of scanned data. Caveat emptor!